Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study - PubMed
7 hours ago
- #real-world-study
- #alopecia-areata
- #ritlecitinib
- Ritlecitinib, a selective inhibitor of Janus kinase 3 and TEC kinases, was studied for severe alopecia areata.
- A 24-week, observational, retrospective study in Italy involved 102 patients aged ≥12 with SALT ≥50.
- 40.2% of patients achieved SALT ≤20 at week 24, with better response in adolescents (48.6%) than adults (21.9%).
- Mean SALT score decreased from 86.2 to 40.8, showing significant hair regrowth.
- Improvements were noted in eyebrows, eyelashes, nails, and quality of life.
- Adverse events were mild (e.g., acne, headache), with only one discontinuation due to severe anemia.
- Ritlecitinib 50 mg/day was effective and well-tolerated, particularly in adolescents.